Cargando…

SERS Immunosensors for Cancer Markers Detection

Early diagnosis and monitoring are essential for the effective treatment and survival of patients with different types of malignancy. To this end, the accurate and sensitive determination of substances in human biological fluids related to cancer diagnosis and/or prognosis, i.e., cancer biomarkers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Geka, Georgia, Kanioura, Anastasia, Likodimos, Vlassis, Gardelis, Spiros, Papanikolaou, Nikolaos, Kakabakos, Sotirios, Petrou, Panagiota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221005/
https://www.ncbi.nlm.nih.gov/pubmed/37241360
http://dx.doi.org/10.3390/ma16103733
_version_ 1785049353206890496
author Geka, Georgia
Kanioura, Anastasia
Likodimos, Vlassis
Gardelis, Spiros
Papanikolaou, Nikolaos
Kakabakos, Sotirios
Petrou, Panagiota
author_facet Geka, Georgia
Kanioura, Anastasia
Likodimos, Vlassis
Gardelis, Spiros
Papanikolaou, Nikolaos
Kakabakos, Sotirios
Petrou, Panagiota
author_sort Geka, Georgia
collection PubMed
description Early diagnosis and monitoring are essential for the effective treatment and survival of patients with different types of malignancy. To this end, the accurate and sensitive determination of substances in human biological fluids related to cancer diagnosis and/or prognosis, i.e., cancer biomarkers, is of ultimate importance. Advancements in the field of immunodetection and nanomaterials have enabled the application of new transduction approaches for the sensitive detection of single or multiple cancer biomarkers in biological fluids. Immunosensors based on surface-enhanced Raman spectroscopy (SERS) are examples where the special properties of nanostructured materials and immunoreagents are combined to develop analytical tools that hold promise for point-of-care applications. In this frame, the subject of this review article is to present the advancements made so far regarding the immunochemical determination of cancer biomarkers by SERS. Thus, after a short introduction about the principles of both immunoassays and SERS, an extended presentation of up-to-date works regarding both single and multi-analyte determination of cancer biomarkers is presented. Finally, future perspectives on the field of SERS immunosensors for cancer markers detection are briefly discussed.
format Online
Article
Text
id pubmed-10221005
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102210052023-05-28 SERS Immunosensors for Cancer Markers Detection Geka, Georgia Kanioura, Anastasia Likodimos, Vlassis Gardelis, Spiros Papanikolaou, Nikolaos Kakabakos, Sotirios Petrou, Panagiota Materials (Basel) Review Early diagnosis and monitoring are essential for the effective treatment and survival of patients with different types of malignancy. To this end, the accurate and sensitive determination of substances in human biological fluids related to cancer diagnosis and/or prognosis, i.e., cancer biomarkers, is of ultimate importance. Advancements in the field of immunodetection and nanomaterials have enabled the application of new transduction approaches for the sensitive detection of single or multiple cancer biomarkers in biological fluids. Immunosensors based on surface-enhanced Raman spectroscopy (SERS) are examples where the special properties of nanostructured materials and immunoreagents are combined to develop analytical tools that hold promise for point-of-care applications. In this frame, the subject of this review article is to present the advancements made so far regarding the immunochemical determination of cancer biomarkers by SERS. Thus, after a short introduction about the principles of both immunoassays and SERS, an extended presentation of up-to-date works regarding both single and multi-analyte determination of cancer biomarkers is presented. Finally, future perspectives on the field of SERS immunosensors for cancer markers detection are briefly discussed. MDPI 2023-05-15 /pmc/articles/PMC10221005/ /pubmed/37241360 http://dx.doi.org/10.3390/ma16103733 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Geka, Georgia
Kanioura, Anastasia
Likodimos, Vlassis
Gardelis, Spiros
Papanikolaou, Nikolaos
Kakabakos, Sotirios
Petrou, Panagiota
SERS Immunosensors for Cancer Markers Detection
title SERS Immunosensors for Cancer Markers Detection
title_full SERS Immunosensors for Cancer Markers Detection
title_fullStr SERS Immunosensors for Cancer Markers Detection
title_full_unstemmed SERS Immunosensors for Cancer Markers Detection
title_short SERS Immunosensors for Cancer Markers Detection
title_sort sers immunosensors for cancer markers detection
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221005/
https://www.ncbi.nlm.nih.gov/pubmed/37241360
http://dx.doi.org/10.3390/ma16103733
work_keys_str_mv AT gekageorgia sersimmunosensorsforcancermarkersdetection
AT kaniouraanastasia sersimmunosensorsforcancermarkersdetection
AT likodimosvlassis sersimmunosensorsforcancermarkersdetection
AT gardelisspiros sersimmunosensorsforcancermarkersdetection
AT papanikolaounikolaos sersimmunosensorsforcancermarkersdetection
AT kakabakossotirios sersimmunosensorsforcancermarkersdetection
AT petroupanagiota sersimmunosensorsforcancermarkersdetection